Baidu
map

Chem Biol Interact:柴胡皂苷A能够改善 OVA诱导的过敏性鼻炎鼻部炎症

2019-11-16 AlexYang MedSci原创

过敏性鼻炎(AR)是I型超敏免疫响应,并且是一种常见的慢性过敏呼吸道障碍,可通过一种或者更多的鼻部症状来鉴定。尽管关于AR治疗方面有很多研究,而治疗AR的有效药物仍旧很有限。最近,有研究人员在OVA诱导的小鼠AR模型中,阐释了柴胡皂苷A(SSA)对鼻部炎症、T辅助(Th)2和Th17细胞因子、维甲酸相关孤儿核受体(ROR)-γt、信号转导和转录激活因子(STAT)3和细胞核因子(NF)-κB信号的

过敏性鼻炎(AR)是I型超敏免疫响应,并且是一种常见的慢性过敏呼吸道障碍,可通过一种或者更多的鼻部症状来鉴定。尽管关于AR治疗方面有很多研究,而治疗AR的有效药物仍旧很有限。

最近,有研究人员在OVA诱导的小鼠AR模型中,阐释了柴胡皂苷A(SSA)对鼻部炎症、T辅助(Th)2和Th17细胞因子、维甲酸相关孤儿核受体(ROR)-γt、信号转导和转录激活因子(STAT)3和细胞核因子(NF)-κB信号的影响。研究发现,OVA诱导的AR小鼠鼻症状和组织学变化、OVA特异性免疫球蛋白(lg)E/lgG1、ROR-γt, STAT3和NF-κB信号增加。然而,SSA处理能够显著的减少过敏症状包括擦鼻和打喷嚏。另外,鼻组织中的组织学变化在SSA处理后得到了巨大的改善,这些变化包括了粘膜层厚度,杯状细胞增生,嗜酸性粒细胞和肥大细胞浸润。同时,SSA治疗能够减少OVA特异性IgE/IgG1在血清中的水平和Th2和Th17细胞因子在鼻灌洗液(NALF)中的水平。更多的是,SSA能够抑制转录因子ROR-γt、STAT3和磷酸化STAT3在NALF和肺中的激活。更多的是,SSA也能够显著的抑制NF-κB p65和磷酸化NF-κB p65在NALF和肺中的表达。

最后,研究人员指出,他们的研究表明了SSA能够通过调控IL-6/ROR-γt/STAT3/IL-17/NF-κB信号减弱OVA诱导的过敏性鼻炎,并指出SSA也许可以作为过敏性疾病治疗的候选药物。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1738983, encodeId=92fc1e3898342, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Mar 19 14:03:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047187, encodeId=d284204e18736, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Apr 30 16:03:00 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918927, encodeId=c71d191892e52, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jan 01 11:03:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767721, encodeId=a55d1e6772145, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Jun 26 21:03:00 CST 2020, time=2020-06-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1738983, encodeId=92fc1e3898342, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Mar 19 14:03:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047187, encodeId=d284204e18736, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Apr 30 16:03:00 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918927, encodeId=c71d191892e52, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jan 01 11:03:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767721, encodeId=a55d1e6772145, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Jun 26 21:03:00 CST 2020, time=2020-06-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1738983, encodeId=92fc1e3898342, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Mar 19 14:03:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047187, encodeId=d284204e18736, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Apr 30 16:03:00 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918927, encodeId=c71d191892e52, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jan 01 11:03:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767721, encodeId=a55d1e6772145, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Jun 26 21:03:00 CST 2020, time=2020-06-26, status=1, ipAttribution=)]
    2020-01-01 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1738983, encodeId=92fc1e3898342, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Mar 19 14:03:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047187, encodeId=d284204e18736, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Apr 30 16:03:00 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918927, encodeId=c71d191892e52, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jan 01 11:03:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767721, encodeId=a55d1e6772145, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Jun 26 21:03:00 CST 2020, time=2020-06-26, status=1, ipAttribution=)]

相关资讯

World Allergy Organ J:过敏性鼻炎历史和哮喘风险研究

在一些研究中,过敏性鼻炎被质疑是哮喘的一个风险因子,但是该相关性并没有很好的证实。最近,有研究人员通过一个系统的回顾和元分析提出了过敏性鼻炎与哮喘风险相关性的证据。研究人员在Medline、Scopus、ISI会议记录数据库和其他数据库中进行了搜索,截止时间为2019年2月,之后进行人工检索来鉴定报道相对风险评估和过敏性鼻炎和哮喘相关性置信区间的案例对照和群体研究,研究人员排除了代表性的额研究。研

Eur Ann Allergy Clin Immunol:过敏性鼻炎在渗出性中耳炎儿童中的患病率分析

过敏性鼻炎在渗出性中耳炎儿童中的患病率在不同的国家中范围为82%到93%。之前的研究已经鉴定和证明了许多渗出性中耳炎的风险因子。然而,与过敏性鼻炎的相关性仍旧存在争议。最近,有研究人员确定了渗出性中耳炎儿童中过敏性鼻炎的患病率情况,并鉴定了渗出性中耳炎的相关风险因子,与过敏性鼻炎相关的常见过敏原,还确定了渗出性中耳炎儿童的听力阈值。研究共包括了130名儿童。研究发现,渗出性中耳炎儿童中过敏性鼻炎的

Int Forum Allergy Rhinol:类胆碱能神经元D-U87细胞能估促进过敏性鼻炎T辅助细胞2的极化

副交感神经过敏对过敏性鼻炎(AR)的严重度是有贡献的,但是潜在的神经免疫调控的精细机制仍旧不清楚。最近,有研究人员调查了胆碱能神经抑制剂对AR CD4+ T辅助细胞2(Th2)的极化的影响以及潜在的调控机制。研究人员建立了体外D-U87细胞和CD4+ T细胞的共培养模型。研究发现,Th2细胞比例在来源于AR患者的CD4+ T细胞与D-U87细胞共培养后显著增加,但是在异丙托溴铵(IB)处理后减少。

World Allergy Organ J:老年人慢性鼻炎治疗中糠酸莫米松并不比生理盐水效果更好

与老龄化相关疾病的患病率正在增加,其中就有鼻部的问题。慢性鼻炎是老年人中最为常见的鼻部疾病之一。同时,过敏症状会因免疫退化而减少。最近,有研究人员评估了一种皮质类固醇鼻喷雾剂(糠酸莫米松)对鼻腔开放和鼻炎严重度以及生活质量的影响,并与生理盐水喷雾效果进行了比较。研究是一个开放标签随机研究,包括了不小于60岁的慢性鼻炎(过敏性和非过敏性鼻炎)患者。主要的终点是鼻腔开放的改善,次级结果包括了症状的严重

Mol Med Rep:Der p2‑A20 DNA疫苗能够减弱过敏性炎症

过敏性鼻炎(AR)是一种常见的疾病,需要更加方便,安全和有效的抗原特异性免疫疗法。最近,有研究人员调查了鼻内注射能够共表达der p2和a20蛋白的真核表达载体对过敏性鼻炎小鼠的治疗效果。研究人员通过纳米粒子包装pVAX1-Der p2-A20疫苗,并通过建立了Balb/c过敏性鼻炎小鼠模型。之后评估了DNA疫苗对鼻过敏炎症的治疗效果,并通过ELISA确定了lgE,slgE和lgG以及细胞因子水平

Sci Rep:过敏性鼻炎是胃食管反流病的一种风险因素

胃食管反流病(GERD)能够引起一些上呼吸道症状,并改变鼻咽粘膜的生理,而反过来上呼吸道疾病同样可能加剧GERD症状。长久以来,哮喘被认为是GERD的一种风险因素。根据相似的流行病学与病理生理学,哮喘和过敏性鼻炎(AR)通常被鉴定为联合气道疾病;然而,AR与GERD的相关性仍旧还没有阐明。最近,有研究人员评估了是否AR能够增加GERD的风险。研究人员从健康保险数据库中鉴定了诊断为AR的患者,时间为

Baidu
map
Baidu
map
Baidu
map